TY - JOUR
T1 - Achieving the Lowest Effective Antipsychotic Dose for Patients with Remitted Psychosis
T2 - A Proposed Guided Dose-Reduction Algorithm
AU - Liu, Chen Chung
AU - Takeuchi, Hiroyoshi
N1 - Funding Information:
Chen-Chung Liu received research Grants MOST 106-2314-B-002-106 and MOST 107-2314-B-002-222-MY3 from the Ministry of Science and Technology, Taiwan. Chen-Chung Liu has also received speaker’s honoraria from Janssen-Cilag Pharma. Hiroyoshi Takeuchi has received research grants from the Japan Society for the Promotion of Science, Japan Agency for Medical Research and Development, and SENSHIN Medical Research Foundation. Hiroyoshi Takeuchi has also received speaker’s honoraria from Meiji-Seika Pharma, Mochida, Otsuka, Sumitomo Dainippon Pharma, and Yoshitomi Yakuhin, and manuscript fees from Sumitomo Dainippon Pharma. The funding sources did not participate in the preparation, review, approval, or decision to submit this manuscript for publication.
Publisher Copyright:
© 2019, Springer Nature Switzerland AG.
PY - 2020/2/1
Y1 - 2020/2/1
N2 - Continuing antipsychotic treatment in patients with schizophrenia under clinical remission remains controversial. Even though the mainstream opinion declares an outweighed balance against medication discontinuation, recent reviews and critiques suggest that some patients may remain symptom free and well functioning after stopping antipsychotics, but few predictors can identify who can try medication discontinuation, whilst no guidelines exist for reducing medication to reach the lowest effective dose safely. Analyzing the findings from studies employing different methodologies, adopting evidence from pharmacodynamic research, and observing dose reduction in stable patients, as well as taking inspiration from the metaphor of the Cantor set in natural philosophy, we introduce an alternative solution and propose a guided dose-reduction algorithm that follows a set of clear precautions and instructions. The algorithm recommends only a fraction (no more than 25%) of the dosage to be reduced at a time, with at least a 6-month stabilization period required before reducing another 25% of the dose. Patients are empowered to actively participate in decision making when they are ready for further dose tapering, or should they retreat to a previous dosage if warning signs of a relapse re-emerge. An intermittent or irregular dosing schedule can be used to adapt this algorithm to real-world practice. Our preliminary findings suggest that patients with remitted psychosis can do well along this path. We anticipate that this approach can help optimize the risk–benefit ratio and instill a hope in patients with schizophrenia that they can maintain in stable remission under a lower antipsychotic dose without an increased risk of relapse.
AB - Continuing antipsychotic treatment in patients with schizophrenia under clinical remission remains controversial. Even though the mainstream opinion declares an outweighed balance against medication discontinuation, recent reviews and critiques suggest that some patients may remain symptom free and well functioning after stopping antipsychotics, but few predictors can identify who can try medication discontinuation, whilst no guidelines exist for reducing medication to reach the lowest effective dose safely. Analyzing the findings from studies employing different methodologies, adopting evidence from pharmacodynamic research, and observing dose reduction in stable patients, as well as taking inspiration from the metaphor of the Cantor set in natural philosophy, we introduce an alternative solution and propose a guided dose-reduction algorithm that follows a set of clear precautions and instructions. The algorithm recommends only a fraction (no more than 25%) of the dosage to be reduced at a time, with at least a 6-month stabilization period required before reducing another 25% of the dose. Patients are empowered to actively participate in decision making when they are ready for further dose tapering, or should they retreat to a previous dosage if warning signs of a relapse re-emerge. An intermittent or irregular dosing schedule can be used to adapt this algorithm to real-world practice. Our preliminary findings suggest that patients with remitted psychosis can do well along this path. We anticipate that this approach can help optimize the risk–benefit ratio and instill a hope in patients with schizophrenia that they can maintain in stable remission under a lower antipsychotic dose without an increased risk of relapse.
UR - http://www.scopus.com/inward/record.url?scp=85075284881&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85075284881&partnerID=8YFLogxK
U2 - 10.1007/s40263-019-00682-8
DO - 10.1007/s40263-019-00682-8
M3 - Article
C2 - 31741178
AN - SCOPUS:85075284881
SN - 1172-7047
VL - 34
SP - 117
EP - 126
JO - CNS Drugs
JF - CNS Drugs
IS - 2
ER -